Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Failed Post-MI Trial Foils Novartis' Higher ASPIRE-ations For Tekturna

This article was originally published in The Pink Sheet Daily

Executive Summary

ACC panelist: Study was not powered for outcomes, but doubling in death rates is still "very disturbing."

You may also be interested in...



Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC

Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting

Novartis Takes Cardiovascular Setbacks In Stride After Poor Showing At ACC

Novartis' strategy to expand its cardiovascular and metabolics business in advance of the patent expiry of its blockbuster Diovan included running a lot of clinical trials to add indications and amass outcomes data. But studies designed to expand use also have the potential to disappoint, as was the case for several trials presented at the American College of Cardiology annual meeting

Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis

Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS070352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel